

# STATE OF NEW YORK

6628

2021-2022 Regular Sessions

## IN ASSEMBLY

March 23, 2021

Introduced by M. of A. BARCLAY, MANKTELOW, SALKA, LEMONDES, DeSTEFANO,  
M. MILLER, J. M. GIGLIO, BLANKENBUSH -- read once and referred to the  
Committee on Health

AN ACT to amend the public health law, in relation to designating an  
individual to be notified in the case of dose or brand change for  
psychotropic medication

The People of the State of New York, represented in Senate and Assem-  
bly, do enact as follows:

1 Section 1. Subdivision 3 of section 2803-c of the public health law is  
2 amended by adding a new paragraph s to read as follows:

3 s. (i) Pursuant to regulations promulgated by the commissioner, every  
4 patient shall have the right to designate an individual to be notified  
5 in the event that the facility reduces the dose or changes the brand or  
6 form of the patient's psychotropic medication. Such notification shall  
7 include a warning listing possible side effects and drug interactions,  
8 including side effects upon discontinuation of such drugs. Notification  
9 shall be made in writing, and shall not be effective until receipt of  
10 the written consent of the designated individual. In the case of a grad-  
11 ual dose reduction, a designee shall check a box acknowledging such  
12 designee has been given a copy of the rights pertaining to gradual dose  
13 reductions.

14 (ii) For the purposes of this paragraph, "psychotropic medication"  
15 means a medication that is administered for the purpose of affecting  
16 brain activities associated with mental processes and behavior, includ-  
17 ing, but not limited to, anti-psychotics, anti-depressants, anxiolytics,  
18 sedatives and hypnotics.

19 § 2. This act shall take effect on the one hundred eightieth day after  
20 it shall have become a law.

EXPLANATION--Matter in italics (underscored) is new; matter in brackets  
[-] is old law to be omitted.

LBD03002-02-1